PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial
PainReform Ltd. is advancing its drop-less OcuRing-K therapy, designed for post-cataract pain and inflammation, toward a Phase II clinical trial in the U.S. in collaboration with LayerBio. The therapy aims to provide consistent control with lower drug exposure than traditional eye drops. Future updates will follow as the program progresses.
PainReform Ltd. has announced the commencement of its development plan for OcuRing™-K, an innovative, drop-less, sustained-release ocular therapy designed to deliver controlled ketorolac following cataract surgery. The company, in collaboration with LayerBio, is advancing OcuRing-K toward a Phase II clinical trial in the United States. The initial target indication is for post-cataract pain and inflammation, with the goal of providing consistent control with significantly lower drug exposure than traditional eye drops. The research and development efforts are ongoing, and future updates will be provided as the program progresses. No specific scientific research results have been presented yet; the results will be generated and shared following the next stages of clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595303-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
